Regarding the 2011 ENMC diagnostic criteria, we did not find significant differences in anti-cN1A antibody prevalence within the three diagnostic groups (clinicopathologically defined IBM 39.5%, clinically defined IBM 35.7% and probable IBM 28.6%, p = 0.863). The gene discussed is NT5C1A; the disease is inclusion body myositis.